NCTR – July 27th, 2010
The latest issue of the New Companies & Technologies Report (NCTR) has been published on innovative companies and technologies in health and medicine. * If […]
The latest issue of the New Companies & Technologies Report (NCTR) has been published on innovative companies and technologies in health and medicine. * If […]
The information could allow researchers to observe cellular changes as a patient undergoes cancer treatment, and could aid in the development of new molecular therapeutics for diseases such as cancer.
An experimental drug from Nektar Therapeutics was able to shrink tumors and reduce a cancer biomarker in women with advanced ovarian cancer in a mid-stage study.
A disease that affects a significant number of Americans, that requires extensive and often frustrating lifestyle modifications, and that has no approved pharmaceutical treatment: It’s an enticing opportunity for drug companies.
Though selected in order to give a platform to lesser recognized businesses, the companies presenting demonstrated the vast diversity of the healthcare and life science spaces.
As President Obama prepares to release his U.S. AIDS strategy, at least one pharmaceutical company is readying a crucial clinical trial of its vaccine against HIV/AIDS.
Celgene has acquired Abraxis BioScience in a cash-and-stock deal valued at $2.9 billion, reports FierceBiotech.
OneMedPlace announced that it will showcase to investors and entrepreneurs the newest and most promising new medical technologies in the region.
The company is a medical devices company that has developed a novel technology for site directed, electronic driven radiation therapy for the treatment of cancer. […]
The company is a medical device company that has developed a cutting edge catheter-based drug delivery technology that enables the delivery of drugs to highly […]
Copyright © 2025 | WordPress Theme by MH Themes